Osaka, Japan

Hiroya Takizawa


 

Average Co-Inventor Count = 8.0

ph-index = 1

Forward Citations = 1(Granted Patents)


Company Filing History:


Years Active: 2022

Loading Chart...
Loading Chart...
1 patent (USPTO):Explore Patents

Title: Hiroya Takizawa: Innovator in Dihydronaphthalene Derivatives

Introduction

Hiroya Takizawa is a prominent inventor based in Osaka, Japan. He has made significant contributions to the field of medicinal chemistry, particularly through his innovative work on dihydronaphthalene derivatives. His research focuses on developing compounds that can potentially treat neurodegenerative diseases.

Latest Patents

Hiroya Takizawa holds a patent for a dihydronaphthalene derivative, which is represented by a general formula (I). This compound exhibits selective S1P5 receptor agonist activity, attributed to its unique linker structure connecting a phenyl group to a cyclic substituent within the dihydronaphthalene skeleton. The compound's design allows it to serve as a therapeutic agent for S1P5-mediated diseases, including schizophrenia.

Career Highlights

Throughout his career, Takizawa has been associated with Ono Pharmaceutical Co., Ltd., where he has contributed to various research initiatives. His work has been instrumental in advancing the understanding of receptor agonists and their potential applications in treating complex diseases.

Collaborations

Hiroya Takizawa has collaborated with notable colleagues, including Kensuke Kusumi and Haruto Kurata. These partnerships have fostered a collaborative environment that enhances the research and development of innovative pharmaceutical solutions.

Conclusion

Hiroya Takizawa's contributions to the field of medicinal chemistry, particularly through his patented dihydronaphthalene derivative, highlight his role as an influential inventor. His work continues to pave the way for advancements in the treatment of neurodegenerative diseases.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…